Highlights
- Net loss was $119,036 thousand for the third quarter of 2026, compared with $162,253 thousand a year earlier.
- Recursion completed an offering of 61.5 million shares on October 16, 2026, for net proceeds of approximately $187.2 million.
- After 12 weeks of REC-4881, 13 of 15 adult TUPELO patients had a reduction in total polyp burden.
- Management said it expects 2027 cash operating expenses of less than $360 million and a cash runway extending into 2029.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares were trading at USD 2.58 on November 17, 2026, down 11.19%, with a relative Volume at time of 2.35. The clinical-stage AI-enabled drug discovery company completed a stock offering on October 16, 2026, announced further TUPELO trial data for REC-4881 on November 2 and filed its Form 10-Q for the quarter ended September 30, 2026, on November 2.
Recursion is a Delaware corporation with principal executive offices in Salt Lake City, Utah. It describes itself as a clinical-stage company in AI-enabled drug discovery and development, advancing wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas. Its Recursion OS is an AI-native platform that integrates biology, chemistry and clinical development. The company operates as a single operating segment, reports on a fiscal year ending December 31, and has employees primarily in the United States, United Kingdom and Canada. It has no products approved for commercial sale. As of October 26, 2026, 622,759,259 shares of Class A common stock were outstanding.
Third Quarter Results
For the quarter ended September 30, 2026, Recursion reported total Revenue of $18,552 thousand, compared with $5,175 thousand a year earlier. The company said the revenue change was primarily due to its Sanofi partnership, for which it achieved a $10.0 million milestone for an immunology small molecule development candidate.
Research and development expense was $99,122 thousand and general and administrative expense was $32,561 thousand. Loss from operations was $123,176 thousand, compared with $172,202 thousand. The net loss was $119,036 thousand, or $0.22 per share, compared with a net loss of $162,253 thousand, or $0.36 per share.
Stock Offering, Cash and Capital
On October 16, 2026, Recursion completed the offering and sale of 61.5 million shares of Class A common stock for net proceeds of approximately $187.2 million. On the call, management said pro forma cash and equivalents were $749 million as of September 30, 2026, including net proceeds from the offering.
At September 30, 2026, cash and cash equivalents were $549,853 thousand, compared with $743,294 thousand at December 31, 2025. Cash used in Operating Activities for the nine months was $264,454 thousand, compared with $325,735 thousand. The accumulated Deficit was $2.4 billion. The company said it anticipates that it will need to raise additional financing in the future, and that its cash and cash equivalents should fund operations for at least the next twelve months based on its current operating plan.
TUPELO and Pipeline Updates
On November 2, 2026, Recursion announced further data from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational oral MEK1/2 inhibitor in development for familial adenomatous polyposis. After 12 weeks of REC-4881 at 4 mg once daily, 87% of adult patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction. The highest-grade treatment-related adverse event was Grade 1 or 2 in 21 of 26 patients and Grade 3 in four patients.
For REC-1245, early data from the Phase 1 portion of the DAHLIA study showed three partial responses per RECIST 1.1 criteria, two confirmed and one unconfirmed. Sanofi optioned the first development candidate from its collaboration with Recursion, which triggered a $10 million milestone payment.
Outlook
Recursion anticipates initiating a registrational trial of REC-4881 in the second half of 2027, pending ongoing FDA discussions. It expects preliminary REC-1245 dose-expansion data in endometrial cancer in the second half of 2027.
On the call, management said it lowered its 2026 cash Operating Expense guidance from $390 million to less than $375 million, excluding Partnership inflows and one-time expenses. It said it expects 2027 cash operating expenses of less than $360 million and now expects its cash runway to extend into 2029.






Please wait processing your request...